<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302365</url>
  </required_header>
  <id_info>
    <org_study_id>CTS-5043</org_study_id>
    <nct_id>NCT02302365</nct_id>
  </id_info>
  <brief_title>Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion</brief_title>
  <acronym>WBCD</acronym>
  <official_title>Multicenter, Retrospective Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terumo BCT</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Terumo BCT</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, retrospective data collection of routine clinical use with the
      Spectra Optia® apheresis system for white blood cell depletion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to gather a broader knowledge and information from routine clinical
      use on the performance and safety of white blood cell depletion procedures with the Spectra
      Optia® apheresis system.

      In order to do so, retrospective data on white blood cell depletion procedures with the
      Spectra Optia® apheresis system done in routine use in 3 different centers will be collected
      and analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Decrease in White Blood Cell Count in Patient Following Apheresis Procedure</measure>
    <time_frame>immediately after apheresis procedure: on average this will be within 15 minutes after the end of the procedure</time_frame>
    <description>Percent decrease in WBC count calculation: (WBCpre - WBCpost) / WBCpre x 100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collection Efficiency (CE) for WBC (or Percent of Processed WBCs) Achieved by Spectra Optia.</measure>
    <time_frame>immediately after apheresis procedure: on average this will be within 15 minutes after the end of the procedure</time_frame>
    <description>Collection efficiency for WBC achieved by Spectra Optia System calculation: (WBC/µL depletion product x depletion product volume) / (WBCpre + WBCpost) / 2 x total processed blood volume)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Participants were followed for the duration of the procedure and for up to 24 hours after the procedure.</time_frame>
    <description>Adverse events were defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medical device, whether or not considered related to the medical device and/or procedure. Therefore, an AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the medical device and/or procedure.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Pre-procedure WBC Count</measure>
    <time_frame>Prior to Each Spectra Optia Apheresis Procedure</time_frame>
    <description>Pre-procedure WBC count</description>
  </other_outcome>
  <other_outcome>
    <measure>Post-procedure WBC Count</measure>
    <time_frame>Following apheresis procedure</time_frame>
    <description>Post-procedure WBC count</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient's Platelet Count Pre-depletion Procedure</measure>
    <time_frame>Prior to Each Spectra Optia Apheresis Procedure</time_frame>
    <description>Patient's platelet count pre-depletion procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient's Platelet Count Post-depletion Procedure</measure>
    <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
    <description>Patient's platelet count post-depletion procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Whole Blood Processed (mL)</measure>
    <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
    <description>Volume of patient's blood processed in mL during the apheresis procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Whole Blood Flow mL/Min</measure>
    <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
    <description>Whole Blood Flow in mL/min measured during the white blood cell depletion procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Procedure Duration</measure>
    <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
    <description>The duration of the WBCD procedure measured in minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>Platelet Change (% Change)</measure>
    <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
    <description>% change in patient's pre and post-depletion procedure platelet counts</description>
  </other_outcome>
  <other_outcome>
    <measure>Waste Bag Volume</measure>
    <time_frame>Post each Spectra Optia Apheresis Procedure</time_frame>
    <description>Volume of the depletion product</description>
  </other_outcome>
  <enrollment type="Actual">43</enrollment>
  <condition>Leukocytosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spectra Optia® Apheresis System</intervention_name>
    <description>White Blood Cell Depletion</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have undergone white blood cell depletion via the Spectra Optia Apheresis
        System which is likely to include patients with severe leukocytosis in acute leukemia
        (acute myeloid leukemia, acute lymphoblastic leukemia, or in chronic myelogenous leukemia)
        or to prevent tumor lysis syndrome.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients having received a minimum of 1 white blood cell depletion procedure via the
             Spectra Optia Apheresis System

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isobelle Galeon, MD, MPH, MSCS</last_name>
    <role>Study Director</role>
    <affiliation>Medical Monitor, Clinical Safety</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Transfusion Medicine and Immunohaematology, German Red Cross Blood Donor Service Baden-Württemberg-Hessen gGmbH, Johann-Wolfgang-Goethe-University Hospital</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Istvan and Szent Laszlo Hospital of Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <results_first_submitted>November 12, 2015</results_first_submitted>
  <results_first_submitted_qc>February 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2016</results_first_posted>
  <last_update_submitted>July 2, 2018</last_update_submitted>
  <last_update_submitted_qc>July 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>white blood cell depletion</keyword>
  <keyword>apheresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukocytosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02302365/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 18, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02302365/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subjects Who Received a Minimum of 1 WBCD Procedure</title>
          <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>0-2 Hour Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43">Data were collected from 58 WBCD procedures performed in 43 subjects - Full and Safety Analysis Sets</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41">The Per-protocol Analysis Set comprised 54 procedures performed in 41 subjects</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>0-24 Hour Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32">2 of 3 study sites collected additional safety data; 32 pts. 0-24 hour data, 43 pts. 0-2 hour data</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System.</population>
      <group_list>
        <group group_id="B1">
          <title>Subjects Who Received At Least 1 WBCD Apheresis Procedure</title>
          <description>Eligible subjects who received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.9" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.2" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.9" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Blood Volume</title>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Decrease in White Blood Cell Count in Patient Following Apheresis Procedure</title>
        <description>Percent decrease in WBC count calculation: (WBCpre - WBCpost) / WBCpre x 100%</description>
        <time_frame>immediately after apheresis procedure: on average this will be within 15 minutes after the end of the procedure</time_frame>
        <population>The Full Analysis Set comprised all 43 patients (58 procedures) for whom WBCD data were collected. One patient terminated the first procedure prematurely and therefore did not have post-procedure data, resulting in a total of 57 units analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>WBCD Procedures Performed</title>
            <description>Eligible subjects received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System; 58 WBCD procedures were performed in 43 patients</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Decrease in White Blood Cell Count in Patient Following Apheresis Procedure</title>
          <description>Percent decrease in WBC count calculation: (WBCpre - WBCpost) / WBCpre x 100%</description>
          <population>The Full Analysis Set comprised all 43 patients (58 procedures) for whom WBCD data were collected. One patient terminated the first procedure prematurely and therefore did not have post-procedure data, resulting in a total of 57 units analyzed.</population>
          <units>% change in subject's WBC count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" spread="21.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Collection Efficiency (CE) for WBC (or Percent of Processed WBCs) Achieved by Spectra Optia.</title>
        <description>Collection efficiency for WBC achieved by Spectra Optia System calculation: (WBC/µL depletion product x depletion product volume) / (WBCpre + WBCpost) / 2 x total processed blood volume)</description>
        <time_frame>immediately after apheresis procedure: on average this will be within 15 minutes after the end of the procedure</time_frame>
        <population>The CE of the WBCD procedures was measured from the waste bag (depletion product) contents from Sites 2 and 3. WBC counts were not available from the waste bags for subjects treated at Site 1.</population>
        <group_list>
          <group group_id="O1">
            <title>WBCD Procedures Performed</title>
            <description>Eligible subjects received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System; 58 WBCD procedures were performed in 43 patients</description>
          </group>
        </group_list>
        <measure>
          <title>Collection Efficiency (CE) for WBC (or Percent of Processed WBCs) Achieved by Spectra Optia.</title>
          <description>Collection efficiency for WBC achieved by Spectra Optia System calculation: (WBC/µL depletion product x depletion product volume) / (WBCpre + WBCpost) / 2 x total processed blood volume)</description>
          <population>The CE of the WBCD procedures was measured from the waste bag (depletion product) contents from Sites 2 and 3. WBC counts were not available from the waste bags for subjects treated at Site 1.</population>
          <units>percent of processed WBCs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Adverse events were defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medical device, whether or not considered related to the medical device and/or procedure. Therefore, an AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the medical device and/or procedure.</description>
        <time_frame>Participants were followed for the duration of the procedure and for up to 24 hours after the procedure.</time_frame>
        <population>Full and Safety Analysis Sets. 53.5% of subjects with acute myeloid leukemia (AML), 18.6% of subjects with chronic lymphocytic leukemia, &lt; 10% of subjects with other diagnoses. The WBCD procedure was performed most frequently to treat leukocytosis (44.2%), to prevent tumor lysis syndrome (34.9%), or to treat increased blood viscosity (20.9%).</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Data Collection 0-2 Hours Post Apheresis Procedure</title>
            <description>58 WBCD procedures were performed in 43 patients. Safety data was collected for up to 2 hours post apheresis procedure</description>
          </group>
          <group group_id="O2">
            <title>Safety Data Collection 0-24 Hours Post Apheresis Procedure</title>
            <description>41 WBCD procedures were performed in 32 patients. Safety data was collected for up to 24 hours post apheresis procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Adverse events were defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medical device, whether or not considered related to the medical device and/or procedure. Therefore, an AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the medical device and/or procedure.</description>
          <population>Full and Safety Analysis Sets. 53.5% of subjects with acute myeloid leukemia (AML), 18.6% of subjects with chronic lymphocytic leukemia, &lt; 10% of subjects with other diagnoses. The WBCD procedure was performed most frequently to treat leukocytosis (44.2%), to prevent tumor lysis syndrome (34.9%), or to treat increased blood viscosity (20.9%).</population>
          <units>Number of subjects with at least 1 TEAE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pre-procedure WBC Count</title>
        <description>Pre-procedure WBC count</description>
        <time_frame>Prior to Each Spectra Optia Apheresis Procedure</time_frame>
        <population>The Full Analysis Set comprised all 43 patients (58 procedures) for whom WBCD data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>WBCD Procedures Performed</title>
            <description>58 WBCD procedures were performed in 43 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-procedure WBC Count</title>
          <description>Pre-procedure WBC count</description>
          <population>The Full Analysis Set comprised all 43 patients (58 procedures) for whom WBCD data were collected.</population>
          <units>cells x 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.5" spread="175.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Post-procedure WBC Count</title>
        <description>Post-procedure WBC count</description>
        <time_frame>Following apheresis procedure</time_frame>
        <population>Data were collected on a total of 58 procedures, however one patient terminated the first procedure prematurely and therefore did not have post-procedure data.</population>
        <group_list>
          <group group_id="O1">
            <title>WBCD Procedures Performed</title>
            <description>58 WBCD procedures were performed in 43 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-procedure WBC Count</title>
          <description>Post-procedure WBC count</description>
          <population>Data were collected on a total of 58 procedures, however one patient terminated the first procedure prematurely and therefore did not have post-procedure data.</population>
          <units>cells x 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>procedure</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedure</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.9" spread="156.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient's Platelet Count Pre-depletion Procedure</title>
        <description>Patient's platelet count pre-depletion procedure</description>
        <time_frame>Prior to Each Spectra Optia Apheresis Procedure</time_frame>
        <population>Full and Safety Analysis Sets.</population>
        <group_list>
          <group group_id="O1">
            <title>WBCD Procedures Performed</title>
            <description>58 WBCD procedures were performed in 43 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Platelet Count Pre-depletion Procedure</title>
          <description>Patient's platelet count pre-depletion procedure</description>
          <population>Full and Safety Analysis Sets.</population>
          <units>cells x 10^3/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1" spread="75.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient's Platelet Count Post-depletion Procedure</title>
        <description>Patient's platelet count post-depletion procedure</description>
        <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
        <population>Full and Safety Analysis Sets. Data were collected on a total of 58 procedures, however one patient terminated her first procedure prematurely and therefore did not have post-procedure data.</population>
        <group_list>
          <group group_id="O1">
            <title>WBCD Procedures Performed</title>
            <description>58 WBCD procedures were performed in 43 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Platelet Count Post-depletion Procedure</title>
          <description>Patient's platelet count post-depletion procedure</description>
          <population>Full and Safety Analysis Sets. Data were collected on a total of 58 procedures, however one patient terminated her first procedure prematurely and therefore did not have post-procedure data.</population>
          <units>cells x 10^3/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="53.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Whole Blood Processed (mL)</title>
        <description>Volume of patient's blood processed in mL during the apheresis procedure</description>
        <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
        <population>Full and Safety Analysis Sets</population>
        <group_list>
          <group group_id="O1">
            <title>WBCD Procedures Performed</title>
            <description>58 WBCD procedures were performed in 43 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Whole Blood Processed (mL)</title>
          <description>Volume of patient's blood processed in mL during the apheresis procedure</description>
          <population>Full and Safety Analysis Sets</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11395" spread="4010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Total Blood Volumes (TBV) Processed</title>
        <description>Number of times the patient's TBV was processed during the apheresis procedure based on the patient's estimated TBV (Estimated by Nadler's formula for total blood volume of a human being based on gender, height, and weight).</description>
        <time_frame>Post each Spectra Optia Apheresis Procedure</time_frame>
        <population>Full and Safety Analysis Sets</population>
        <group_list>
          <group group_id="O1">
            <title>WBCD Procedures Performed</title>
            <description>58 WBCD procedures were performed in 43 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Blood Volumes (TBV) Processed</title>
          <description>Number of times the patient's TBV was processed during the apheresis procedure based on the patient's estimated TBV (Estimated by Nadler's formula for total blood volume of a human being based on gender, height, and weight).</description>
          <population>Full and Safety Analysis Sets</population>
          <units>TBV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Whole Blood Flow mL/Min</title>
        <description>Whole Blood Flow in mL/min measured during the white blood cell depletion procedure</description>
        <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
        <population>Full and Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>WBCD Procedures Performed</title>
            <description>58 WBCD procedures were performed in 43 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Whole Blood Flow mL/Min</title>
          <description>Whole Blood Flow in mL/min measured during the white blood cell depletion procedure</description>
          <population>Full and Safety Analysis Set</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.3" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Procedure Duration</title>
        <description>The duration of the WBCD procedure measured in minutes</description>
        <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
        <population>Full and Safety Analysis Sets</population>
        <group_list>
          <group group_id="O1">
            <title>WBCD Procedures Performed</title>
            <description>58 WBCD procedures were performed in 43 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Duration</title>
          <description>The duration of the WBCD procedure measured in minutes</description>
          <population>Full and Safety Analysis Sets</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237.3" spread="97.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Platelet Change (% Change)</title>
        <description>% change in patient's pre and post-depletion procedure platelet counts</description>
        <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
        <population>Data were collected on a total of 58 procedures, however one patient terminated her first procedure prematurely and therefore did not have post-procedure data.</population>
        <group_list>
          <group group_id="O1">
            <title>WBCD Procedures Performed</title>
            <description>58 WBCD procedures were performed in 43 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Change (% Change)</title>
          <description>% change in patient's pre and post-depletion procedure platelet counts</description>
          <population>Data were collected on a total of 58 procedures, however one patient terminated her first procedure prematurely and therefore did not have post-procedure data.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="62.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Waste Bag Volume</title>
        <description>Volume of the depletion product</description>
        <time_frame>Post each Spectra Optia Apheresis Procedure</time_frame>
        <population>Full and Safety Analysis Sets; One patient terminated the first procedure prematurely, resulting in a total of 57 units analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>WBCD Procedures Performed</title>
            <description>58 WBCD procedures were performed in 43 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Waste Bag Volume</title>
          <description>Volume of the depletion product</description>
          <population>Full and Safety Analysis Sets; One patient terminated the first procedure prematurely, resulting in a total of 57 units analyzed.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1371.2" spread="896.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data (including serious adverse events [SAEs]) were collected from the time of the start of the WBCD procedure through 2 hours post-procedure for 43 patients and 58 procedures. Adverse event data (including serious adverse events [SAEs]) were collected from the time of the start of the WBCD procedure through 24 hours post-procedure for 32 patients and 41 procedures.</time_frame>
      <desc>Adverse events were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, and coded using the Medical Dictionary for Regulatory Activities (MedDRA®, version 17.0).</desc>
      <group_list>
        <group group_id="E1">
          <title>0-2 Hour Safety Data Collection</title>
          <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System; safety data collected for 2 hours post apheresis procedure</description>
        </group>
        <group group_id="E2">
          <title>0-24 Hour Safety Data Collection</title>
          <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System; safety data collected for 24 hours post apheresis procedure</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA®, version 17</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA®, version 17</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypogammaglobulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Study Site reserves the right to publish the results of its work on the Study. The timing of publication however shall not exceed the 6 months after completion of the Study. Study Site and the PI agree to submit copies of any manuscript/abstract proposed for publication to Sponsor at least 30 days in advance of the presentation. Sponsor may require the delay of publication for no longer than 90 days for the purpose of filing patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Isobelle Galeon, MD, MPH, MSCS, Medical Monitor Clinical Safety</name_or_title>
      <organization>Terumo BCT</organization>
      <phone>+1 303 542-5166</phone>
      <email>Isobelle.Galeon@Terumobct.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

